evidence table
Quercetin Sleep Randomized Trial Evidence Table
Structured evidence table for Quercetin Sleep Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Quercetin Sleep Randomized Trial | Polyphenols strengthen the intestinal barrier and reduce endotoxemia; cocoa bean shell extracts protected against oxysterol‐induced intestinal damage and improved gut microbiota composition in preclinical models (Alia et al. ). | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Quercetin Sleep Randomized Trial | While many epidemiological studies correlate polyphenol‐rich diets (e.g., Mediterranean diet) with reduced NCCD risk, causality is uncertain due to confounding and measurement error. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Quercetin Sleep Randomized Trial | Controlled trials provide more robust evidence but vary widely in doses, formulations, populations and endpoints. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Quercetin Sleep Randomized Trial | AMP BBB CNS COMT COSMOS CRP (hs‐CRP) CSF EGCG ENB‐2 (ENB) ENS EVOO FMD GAD‐7 (GAD) GM‐CSF (GM) HDL HOMA‐IR (HOMA) IBS IL IR LDL LPS MCI MMSE NADPH NCCD (NCCDs) PHGG PHQ‐9 (PHQ) PSQI PWV RBANS RCT SCFA SD TNF (TNF‐α) 2024 Non‐communicable chronic diseases account for the majority of morbidity and mortality worldwide. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Quercetin Sleep Randomized Trial | These effects are particularly relevant in obesity-associated coronary endothelial dysfunction, where microbial metabolites including trimethylamine N-oxide (TMAO) and lipopolysaccharides (LPS) contribute to oxidative stress and vascular inflammation [,,]. | 3 | Tseng Chi-Nan (2025) | Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome |
| Quercetin Sleep Randomized Trial | This review synthesizes current evidence on the mechanistic roles of probiotics and phytoantioxidants in modulating microbiota-derived metabolites and host signaling pathways. | 3 | Tseng Chi-Nan (2025) | Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome |
| Quercetin Sleep Randomized Trial | These microbial actions are particularly salient in obesity-associated coronary endothelial dysfunction, where gut-derived LPS and TMAO contribute to oxidative stress and immune activation []. | 3 | Tseng Chi-Nan (2025) | Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome |
| Quercetin Sleep Randomized Trial | Cardiometabolic diseases remain a leading cause of global morbidity and mortality, with coronary endothelial dysfunction emerging as a central pathophysiological feature. | 3 | Tseng Chi-Nan (2025) | Probiotics and Phytoantioxidants Target Coronary Endothelial Dysfunction in Irregular Sleep- and Obesity-Associated Cardiometabolic Syndrome |
Source documents